Lung Cancer: Novel Biomarkers and Advances in Targeted Therapy
A special issue of Journal of Respiration (ISSN 2673-527X).
Deadline for manuscript submissions: closed (30 June 2022) | Viewed by 545
Special Issue Editor
Interests: biomarker; lung cancer; molecular pathology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Lung cancer is the leading cause of cancer-related mortality worldwide and a complex and heterogeneous disease to treat.
The development and evolution of new molecular biology techniques have revealed that lung cancer is not a single disease entity, and it is now being subdivided into molecular subtypes with dedicated targeted and chemotherapeutic strategies. Lung cancer classification—more importantly, lung adenocarcinoma subtyping—was the initiator of targeted therapy, maximizing treatment efficacy, avoiding toxicity, and improving survival. Different druggable driver mutations have been described, and their identification has led to the development of personalized medicine with targeted therapies. These genomic alterations include mutations, gene fusions, splice variants, and copy number changes in relevant lung cancer genes, such as EGFR, ALK, ROS1, BRAF, MET, RET, and NTRK. As the number of clinically targetable drivers continues to increase, a thorough understanding of the molecular mechanisms of lung tumorigenesis, identification of resistance mechanisms, and identification of the mechanisms underlying the gain of drug resistance, as well as the best strategies for overcoming such, is required.
We are pleased to invite all investigators to contribute to this Special Issue. Original research articles, case reports, or reviews on any aspect of the biology and molecular mechanisms of lung cancer and therapy are welcome. Relevant topics include, but are not limited to, predictive or prognostic biomarkers, the evaluation of potential new targetable driver alterations that represent potential targets for inhibition, and new insights into the mechanisms of therapy resistance.
Dr. Cristina Teixidó
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Respiration is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- lung cancer
- non-small cell lung cancer (NSCLC)
- small cell lung cancer (SCLC)
- biomarker
- personalized medicine
- targeted therapy
- drug resistance
